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Abstract 
Background: Arsenic poisoning interferes with bone metabolism in laboratory animal 
studies, and human studies suggest lowered bone mass density at elevated exposures. As the 
long-term consequences of developmental arsenic toxicity are poorly known, we carried out a 
clinical pilot study of survivors of the mass arsenic poisoning of bottle-fed infants in Japan in 
1955.  
Objectives: The purpose was to evaluate the association between developmental arsenic 
exposure and physical stature and routine blood chemistry reflecting major organ functions 
more than 50 years later. 
Methods: The study sample consisted of 50 individuals recruited at two hospitals in 
Okayama Prefecture, Japan: 27 known poisoning victims (14 men and 13 women), and 23 
non-exposed local controls of similar age (10 men, 13 women). We collected information 
from physical examinations that included routine blood counts and blood biochemistry.  
Results: The average height of the exposed group was 6.5 cm below that of the unexposed 
group (p = 0.02), while the latter was in accordance with national data for both sexes. In 
addition, the exposed participants had a higher mean (SD) serum concentration of alkaline 
phosphatase (ALP) of 233 (63) U/L than the unexposed participants (191 (44) U/L) (p = 
0.01). No other statistically significant difference was observed, and liver enzymes were 
within normal ranges. 
Conclusions: Adults who had suffered arsenic poisoning during infancy showed decreased 
height and elevated ALP that suggests abnormalities in bone metabolism possibly induced by 
arsenic incorporated in the bone matrix. 
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1. Introduction 
 Chronic exposure arsenic via inhalation or drinking water ingestion is linked to 
cancer of the lung, skin, kidney, and urinary bladder (Straif et al. 2009) and an increased risk 
of a variety of other non-communicable diseases (National Research Council 1999). Apart 
from neurotoxicity, evidence on long-term effects of developmental toxicity of arsenic is 
limited (Vahter 2008), but possible adverse effects on birth outcomes include low birth 
weight (Bloom et al. 2014; Gilbert-Diamond et al. 2016; Kile et al. 2016; Rahman et al. 
2009). Further, a prospective cohort study from Bangladesh suggests an inverse association 
between early-life arsenic exposure from contaminated drinking water and children’s growth 
during infancy (Gardner et al. 2013; Saha et al. 2012). Growth inhibition due to arsenic 
exposure has been supported by laboratory animal studies that show decreased body length 
and femur length (Hu et al. 2012), as well as decreased bone mass density (Wu et al. 2014). A 
cross-sectional study of adult males reported an inverse association between environmental 
arsenic exposure and bone mass density (Akbal et al. 2014). In vitro studies have reported 
arsenic-induced decreased mineralization of osteoblasts in primary cell cultures (Hu et al. 
2012), decreased osteoblast differentiation (Wu et al. 2014), and increased differentiation of 
preosteoclasts (Szymczyk et al. 2006). Arsenate likely substitutes phosphate in the skeletal 
apatite crystals (Lindgren et al. 1982), and arsenic exposure causes a decreased expression of 
alkaline phosphatase (ALP) (Hu et al. 2012), an enzyme that hydrolyzes pyrophosphate and 
provides inorganic phosphate needed for bone mineralization (Millan 2013).  
As further evidence is needed regarding the long-term consequences of 
developmental arsenic toxicity, we carried out a pilot study of surviving patients who were 
poisoned by arsenic in infancy (Yorifuji et al. 2016). The mass arsenic poisoning of bottle-fed 
infants happened in the western part of Japan during the summer of 1955. The cause was 
contaminated milk powder, and the estimated arsenic concentration in the reconstituted milk 
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was about 4-7 mg/L (Dakeishi et al. 2006; Hamamoto 1957). The exposures lasted for about 
four months from the change in formulation of the milk powder in April 1955 until the recall 
on August 24, 1955 (Hamamoto 1957). Approximately 13,000 children were affected and 
manifested skin pigmentation, diarrhea, and fever; more than 100 died from acute poisoning 
(Hamamoto 1957). Unfortunately, long-term follow-up studies of the victims have not been 
carried out, and the absence accessible registries hampers any follow-up studies (Yorifuji et 
al. 2011). 
We recently conducted a pilot study of a small group of poisoned victims and non-
exposed controls of similar age; the primary focus was on the long-term effects of 
developmental arsenic exposure on neurological outcomes more than 50 years later (Yorifuji 
et al. 2016). We found that exposed participants had more unfavorable neuropsychological 
outcomes than the unexposed controls, which is consistent with previous studies suggesting 
developmental neurotoxicity of arsenic exposure (Smith and Steinmaus 2009; Tolins et al. 
2014; Vahter 2008). We are now reporting the results of the general physical examination 
and routine blood chemistry, where we explored a variety of parameters that may reflect 
organ dysfunctions, including bone metabolism. This unique incident of arsenic exposure 
may provide useful information to elucidate whether developmental arsenic exposure results 
in adverse effects that persist through mature ages.  
 
2. Materials and Methods 
2.1 Study setting 
During the period from April 2012 to February 2013, we conducted a retrospective cohort 
study of participants at two hospitals (Okayama Kyoritsu Hospital and Mizushima Kyodo 
Hospital) in Okayama Prefecture, Japan. We selected Okayama Prefecture because the 
Prefecture was the most severely affected area in the country (Hamamoto 1957). We 
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collected information on physical status and blood examination in connection with the regular 
health examinations offered to registered victims and conducted at the two participating 
hospitals. We also collected a urine specimen for arsenic analysis. The unexposed subjects 
were examined by the same methods; blood and urine samples were coded, but blinding of 
the clinical examiner was not possible. Demographic characteristics including past medical 
history were obtained from a questionnaire, but arsenic exposure levels in infancy, duration 
of breastfeeding, and detailed residential history were unavailable. The study setting and 
methods are described in further detail in our previous report (Yorifuji et al. 2016). The study 
was approved by the Institutional Review Boards of Okayama University (protocol No. 487) 
and at each hospital. 
 
2.2 Study participants 
We included 50 participants who provided written, informed consent for participation in the 
study: 27 among known poisoned victims (14 men and 13 women) in Okayama Prefecture 
and 23 local, non-exposed controls (10 men and 13 women). Among those invited, three 
exposed (10.0%) and three non-exposed individuals (11.5%) refused to participate in the 
study.  
The exposed participants were identified in part from the list of victims known to the 
Hikari Association to receive free regular health examinations at the two hospitals (n=15). 
The Hikari Association is a public-interest foundation dedicated to providing permanent 
relief for the victims of the contaminated milk powder. It supports victims through various 
efforts such as benefits, including living allowance, and regular health examinations for those 
who have disabilities or a relevant medical diagnosis. According to the Hikari Association, it 
supports regular health examinations for victims with disorders specific to arsenic poisoning, 
such as skin lesions, mental disorder, or intellectual disability. Among the 15 participants 
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identified through the Association, 12 received benefits for their disorders, while three 
participants did not, because they did not suffer from qualifying disorders. The list of exposed 
participants was supplemented by a list of victims who did not receive regular health 
examinations offered by the Hikari Association but who could be reached through the two 
local hospitals (n= 12); the hospitals offered health care to these victims regardless of their 
current health status and certification.  
We also recruited 23 non-exposed controls from medical staff at the two hospitals, 
including clerks, nurses, and laboratory technicians, at ages similar to the exposed 
participants. None of them had been exposed to the contaminated milk powder during 
infancy, but information whether they were breastfed or formula-fed with other milk powder 
could not be obtained. 
 
2.3 Medical examination 
The regular health examinations recorded physical status (height, weight, blood pressure at 
rest, visual acuity, hearing acuity), blood analyses (complete blood count and biochemical 
blood tests), urine analysis (urine protein, blood, and sugar), chest X-ray, and 
electrocardiogram. The same standardized procedures were used at the two participating 
hospitals. In the present study, we selected physical status including height, weight, and 
blood pressure at rest as well as blood counts and biochemistry as the parameters most 
relevant in regard to childhood arsenic exposure. Neurobehavioral outcomes were analyzed in 
a previous report (Yorifuji et al. 2016). 
 
2.4 Urine arsenic analysis 
During the health examinations, we collected 10 mL spot urine samples for immediate 
freezing at -80°C.The frozen samples were couriered to the National Institute of 
8 
 
Environmental Health, USA for arsenic analysis. The samples were acidified with nitric acid 
before determination of arsenic species by atomic absorption spectrophotometry (ref). 
 
2.5. Statistical analyses 
We compared demographic characteristics between exposed and unexposed participants to 
identify possible confounders. We then compared the clinical results on physical status, blood 
analyses, and urine arsenic analysis between the two groups. Because alcohol status may 
affect blood biochemistry, we repeated the analyses after exclusion of participants who 
reported drinking alcohol every day. In addition, as arsenic is reported to increase risks of 
liver disease, diabetes mellitus, and neurocognitive dysfunctions (Das et al. 2012; Islam et al. 
2011; Maull et al. 2012; Yorifuji et al. 2016), we excluded those diagnosed with these 
diseases before repeating the analyses. We also carried out the same analyses after 
stratification by sex. 
In our previous study, we observed that exposed participants had more unfavorable 
neuropsychological outcomes than the unexposed participants, in particular for Design 
memory subtest from Wide Range Assessment of Memory and Learning 2 and Grooved 
pegboard test (both dominant and non-dominant hands) (Yorifuji et al. 2016). As an 
exploratory analysis not included in the original protocol, we examined the correlation of 
these tests with other clinical outcome parameters significantly associated with exposure 
status in order to ascertain the possible phenotypic pattern of sequelae from arsenic poisoning 
during infancy. 
We used Chi-square tests for binary outcomes and t-tests for continuous outcomes. 
PASW Statistics software (SPSS Japan Inc., version 18.0J) was used for the analyses. We 
report two-sided p values, and those less than 0.05 were considered statistically significant. 
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3. Results 
Demographic characteristics by exposure status are shown in Table 1. While age and sex 
distributions were similar, the unexposed participants were more likely to consume alcohol, 
have higher education, and to be employed. Although not significant, the exposed 
participants were more likely to have been diagnosed with neuropsychiatric disorders (e.g., 
depression and epilepsy). Concentrations of arsenic species in urine were not significantly 
different between the groups (Table 2). 
 Table 3 shows physical status of the participants. The exposed participants had lower 
height (mean, 155.2 cm) compared to the unexposed participants (mean, 161.7 cm) (p = 
0.01). According to the “National Health and Nutrition Survey” conducted in 2012 by the 
Japanese Ministry of Health, Labor, and Welfare, the average height at 50-59 years of age 
was 168.6 cm (SD, 5.7) for men and 156.1 cm (SD, 5.3) for women. The average height in 
unexposed male controls in the present study was 168.6 cm (SD, 7.0) and in females 156.3 
cm (SD, 5.9), both in close agreement with the national average values.  
 Blood chemistry results are shown in Table 4. The exposed participants had higher 
ALP concentrations than the unexposed participants, but other findings were not significantly 
different between the groups. When separated by sex, similar tendencies for ALP were 
observed (Table 5). Even after exclusion of participants with daily alcohol usage (n=7) or 
with diagnosis of liver disease (n=11), diabetes mellitus (n=8), or neuropsychiatric disorders 
(n=8), the findings did not change, i.e., the exposed participants had higher ALP values when 
compared to the unexposed participants, although all results were within the reference 
interval used in Japan. The four participants with a result in the high-normal range (300-350 
U/L) all belonged to the exposed group. 
 In exploratory analyses, we calculated correlation coefficients for height and ALP 
regarding the main neuropsychological outcomes, i.e., Design memory and Grooved 
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pegboard scores. In exposed subjects, the former correlated significantly with subject height 
(r = 0.41, p = 0.04) and ALP (r = -0.47, p = 0.02). Correlation coefficients with pegboard 
scores for the dominant hand were -0.48 (p = 0.01) for height and 0.37 (p = 0.09) for ALP. 
Other neurobehavioral tests showed similar, though weaker, associations. All of these 
tendencies suggested increasing deficits at lower height and higher ALP concentrations, 
while similar tendencies were not found among unexposed participants (data not shown). 
 
4. Discussion 
The present study is unique, as it refers to current health in subjects who, as infants more than 
50 years ago, were exposed to arsenic poisoning from contaminated milk powder (Yorifuji et 
al. 2016). This episode affected thousands of victims, most of whom were infants who 
received the exposure from bottle-feeding. While neurological sequelae were reported in 
exposed subjects at adolescence, very limited follow-up has been accomplished (Dakeishi et 
al. 2006). For the first time, the present study reports the physical status and blood 
examinations of surviving victims at adult age.  
The average height of the exposed group was 6.5 cm below that of the unexposed 
group. Although a small part of this substantial difference could perhaps be attributable to 
body posture, the standardized assessment of height in standing position suggests that the 
observed difference is real. Height may be inversely associated with longevity (He et al. 
2014), but a differential mortality before age 60 years would be unlikely to generate a 
difference in height as large as the one observed. A previous study from this mass arsenic 
poisoning already reported lower height among exposed victims at adolescence, although 
details were not provided (Uehata et al. 1977). In addition, a prospective cohort study from 
Bangladesh suggested an inverse association between early-life exposure to arsenic and 
height at infancy (Gardner et al. 2013; Saha et al. 2012).  
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A possible explanation for decreased height may be related to the similarity between 
arsenate and phosphate, thus leading to replacement of phosphorus by arsenic and 
accumulation of the latter in bone tissue (Hosain et al. 1980; Lindgren et al. 1982). Because 
phosphate is crucial for bone growth and mineralization (Penido and Alon 2012), lack of 
phosphate due to substitution by arsenic may have led to shorter height among the exposed 
participants. Indeed, arsenic may affect bone metabolism, as shown in experimental studies 
(Aybar Odstrcil et al. 2010; Hu et al. 2012; Szymczyk et al. 2006; Wu et al. 2014), and 
arsenic exposure inhibits endochondral ossification and osteoblast differentiation (Aybar 
Odstrcil et al. 2010; Wu et al. 2014). In humans, chronic exposure is associated with 
diminished bone mass density in adult males (Akbal et al. 2014). Of possible relevance, an 
inverse association has been reported between arsenic exposure and the plasma concentration 
of insulin-like growth factor 1 in preschool children (Ahmed et al. 2013). Adverse effects of 
environmental exposure to metals, such as lead and cadmium, on children’s growth and 
insulin-like growth factor 1, support the notion that developmental exposures can affect 
height achieved at adult age (Afeiche et al. 2012; Burns et al. 2012; Fleisch et al. 2013; 
Gardner et al. 2013).  
 In addition, we observed that the average value of ALP was considerably higher 
among the exposed group, compared to the unexposed group. ALP refers to a group of 
phosphomonoesterases that hydrolyze phosphate esters; most of the ALP in serum originates 
from either liver or bone, and higher serum-ALP concentrations occur in diseases affecting 
these organs. The bone-specific ALP is formed in osteoclasts and is thought to be involved in 
the calcification of the bone matrix, with elevated serum concentrations reflecting increased 
bone metabolism and accelerated bone formation (Van Hoof and De Broe 1994; Vroon and 
Israili 1990). Exclusion of subjects with liver disease or daily alcohol use did not materially 
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change the difference in ALP between the two study groups, thus suggesting that changes in 
liver functions did not affect the results.  
Studies conducted in communities with high water-arsenic concentrations have 
demonstrated positive associations of arsenic exposure with higher levels of 
aminotransferases as well as ALP among adult participants currently exposed to arsenic, thus 
suggesting a possible impact of liver dysfunction (Das et al. 2012; Islam et al. 2011). 
However, our study did not reveal any differences between the two groups of subjects in 
aminotransferases or bilirubin, which were generally within the reference intervals, and the 
elevated ALP could therefore not be attributed to liver dysfunction. Rather, the difference in 
ALP may be related to alterations in bone metabolism (Penido and Alon 2012).  
Experimental studies suggest that arsenic causes a decreased expression of ALP (Hu 
et al. 2012), which is opposite in direction to the results of the present study. The exposed 
subjects had a history of arsenic poisoning in infancy but not of any subsequent or current 
arsenic exposure (Table 2), and our findings therefore reflect a long-term response, not an 
effect of a recent or ongoing exposure. The elevated ALP could potentially be due to 
accumulated arsenic in bone tissue and could reflect compensatory changes related to 
abnormal bone metabolism induced by the presence of arsenic. Further clarification of these 
issues will require more extensive studies that compare larger numbers of subjects in regard 
to current and past exposures to arsenic, preferably with characterization of ALP isotypes. 
In contrast, we did not observe significant differences in other blood chemistry 
indicators, including glucose metabolism, neither before nor after exclusion of participants 
with diabetes mellitus. While chronic arsenic exposure is associated with an increased 
diabetes incidence (Maull et al. 2012), this disease is apparently less likely to be triggered by 
early-life exposure to arsenic. On the other hand, this conclusion must remain tentative at this 
point, as the population examined represents survivors that may not reveal the full range of 
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adverse effects induced by arsenic poisoning in infancy (Dakeishi et al. 2006; Yorifuji et al. 
2011). 
In our exploratory analyses, we observed that height and ALP were correlated with 
neuropsychological outcomes in the exposed subjects. Unfavorable neuropsychological 
outcomes in subjects poisoned by arsenic in infancy likely reflect permanent changes in brain 
functions (Yorifuji et al. 2016). While changes in height or ALP are unlikely to be 
mechanistically associated with brain development, the correlations support the notion that 
neuropsychological deficits coexist with decreased height and abnormal ALP concentrations 
as permanent sequelae of arsenic exposure during infancy. 
There are several limitations in the present study. First, the number of subjects 
examined is small because we recruited only surviving victims living in Okayama Prefecture. 
Still, the study sample represents the patient population that could be reasonably identified in 
the local community of Okayama. Apart from the Hikari Association’s register of victims 
receiving compensation, no general listing of victims is available today. Our approach to 
inviting Morinaga milk poisoning victims undergoing routine physical examinations 
therefore represents a feasible and reproducible means of selecting subjects with a history of 
severe arsenic exposure during infancy. However, many victims were probably not known to 
the hospitals, especially milder cases. An additional weakness is that we lack information on 
the total dose of arsenic among the exposed participants. The arsenic concentration differed 
by lot number of the milk powder (Dakeishi et al. 2006), and the duration of bottle-feeding is 
poorly documented in available records, thus making any dose calculation unrealistic. The 
control group was a convenience comparison group matched for age and with similar sex 
distribution, and potential confounders were examined only in stratified analyses due to the 
exploratory nature of the study. However, the results of this study did not change materially 
even after the exclusion of participants with daily alcohol intake or relevant diagnoses. Also, 
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as the exposed subjects examined were provided with ongoing health care support from the 
Hikari Association, it is possible that any blood chemistry abnormalities in the victims were 
alleviated by past or current medical treatment, thereby minimizing differences from the 
unexposed subjects. Among possible confounders, developmental exposures to other 
toxicants, such as lead (Afeiche et al. 2012), could have affected attained height, but such 
exposures could not be quantified, although they would seem to be of little relevance in 
comparison with arsenic poisoning.  
 
5. Conclusions 
The present study showed that adults who suffered arsenic poisoning during infancy had 
lower height and higher serum-ALP concentrations compared to non-exposed subjects of the 
same age. In concert with findings in experimental studies, our results suggest that 
developmental arsenic exposure during infancy can result in skeletal abnormalities, as 
reflected by decreased height at adult age. As high arsenic concentrations may prevail in the 
bone tissue, the increased serum-ALP concentrations likely reflect the presence of altered 
bone metabolism; that may differ from the short-term effects. 
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Table 1. Demographic characteristics of the participants separated by exposure status. 
    Exposed   Unexposed   
p value 
    n=27   n=23   
Age; y, mean (SD) 57.7 (0.4)  57.9 (1.1)  0.32  
Sex; n (%)      
 Male 14 (51.9)  10 (43.5)  0.58  
 Female 13 (48.1)  13 (56.5)   
Hospital; n (%)      
 Okayama Kyoritsu Hospital 17 (63)  10 (43.5)  0.26  
 Mizushima Kyodo Hospital 10 (37)  13 (56.5)   
Smoking status; n (%)      
 Non-smoker 19 (70.4)  15 (65.2)  0.11  
 Smoker 5 (18.5)  1 (4.3)   
 Ex-smoker 3 (11.1)  7 (30.4)   
Alcohol frequency; n (%)      
 Does not/seldom drink 21 (77.8)  8 (34.8)  0.01  
 1-6 times/week 5 (18.5)  9 (39.1)   
 Everyday 1 (3.7)  6 (26.1)   
Educational attainment; n (%)      
 Up to High school 17 (63)  0 (0)  0.00  
 Vocational school or Junior college 7 (25.9)  14 (60.9)   
 University or higher 3 (11.1)  9 (39.1)   
Working status; n (%)      
 Housework/Unemployed 5 (18.5)  0 (0)  0.01  
 Full-time/ Part-time/ Self-employment 17 (63)  23 (100)   
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Other 5 (18.5)  0 (0)   
Past history; n (%)      
 Cardiovascular disease 11 (40.7)  7 (30.4)  0.56  
 Diabetes mellitus 5 (18.5)  3 (13)  0.71  
 Liver disease 6 (22.2)  5 (21.7)  1.00  
 Malignant disease 3 (11.1)  0 (0)  0.24  
 Neuropsychiatric disorder 7 (25.9)  1 (4.3)  0.06  
SD, standard deviation 
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Table 2. Arsenic Species in Urine      
    Exposed   Unexposed   
p value 
  n=27  n=23  
    mean (SD)   mean (SD)     
iAs  (ng /ml) 1.46 (0.69)   1.8 (1.1)   0.14  
MMAs  (ng /ml) 2.23 (195.31)  2.18 (179.18)  0.92  
DMAs  (ng /ml) 25.53 (1763.5)  29.13 (2056.75)  0.51  
Sum of arsenic species  (ng /ml) 29.22 (1932.56)  33.16 (2223.29)  0.51  
       
Ratio iAs/MAs 0.95 (51.45)  1.08 (44.54)  0.33  
Ratio MAs/DMAs 0.1 (9.3)   0.08 (3.73)   0.18  
DMA;  dimethylarsinic acid; MMA, monomethylarsonic acid; iAs, inorganic arsenic; SD, 
standard deviation  
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Table 3. Physical status separated by exposure status.      
    Exposed   Unexposed   
p value 
  n=27  n=23  
    N mean (SD)   N mean (SD)     
Physical status               
 Height; cm 27  155.2 (10.6)  23  161.7 (8.8)  0.02  
   Male 14  161.8 (7.1)  10  168.6 (7)  0.03  
   Female 13  148.1 (9)  13  156.3 (5.9)  0.01  
 Weight; kg 27  57.8 (14.2)  23  60.4 (12.1)  0.49  
   Male 14  62.1 (16.2)  10  69.7 (7.3)  0.18  
   Female 13  53.1 (10.2)  13  53.2 (10)  0.98  
 BMI; kg/m2 27  23.8 (4.3)  23  23.2 (4)  0.58  
   Male 14  23.5 (4.8)  10  25 (3.8)  0.42  
   Female 13  24.2 (3.7)  13  21.8 (3.7)  0.11  
 Systolic BP; mmHg 27  125.7 (15)  23  122.4 (21)  0.51  
 Diastolic BP; mmHg 27  74.6 (11.2)  23  70.9 (12.3)  0.27  
BMI; body mass index; BP, blood pressure; SD, standard deviation 
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Table 4. Complete blood count and biochemical blood test separated by exposure status.     
        Exposed   Unexposed   
p value 
  Reference valuesa  n=27  n=23  
        N mean (SD)   N mean (SD)     
Complete blood count          
 WBC; /µl 3500-9000  27 5538.9 (1695.5)  23 4864.8 (1666.9)  0.16  
 RBC; 104 /µl Male: 490-550; Female: 350-500  27 442.7 (43.4)  23 451.6 (38.4)  0.45  
 Hb; g/dl Male: 14-18; Female: 12-16  27 13.9 (1.3)  23 14.4 (1.1)  0.11  
 Ht; % Male: 40-50; Female: 35-45  27 40.7 (3.5)  23 41.6 (2.8)  0.32  
 Platelet; 104 /µl 15-35  27 23.3 (7.3)  23 22.3 (4.6)  0.57  
Biochemical blood test          
 Total bilirubin; mg/dl 0.2-1.2  23 0.7 (0.3)  23 0.8 (0.5)  0.29  
 GOT; U/L 10-35  27 22.7 (10.1)  23 22.1 (4.7)  0.80  
 GPT; U/L 5-30  27 26.5 (12.7)  23 22.3 (9.3)  0.20  
 γ-GTP; U/L Male: 10-50; Female: 10-30  27 50.3 (37)  23 43.5 (28.9)  0.48  
 ALP; U/L 100-350  23 232.7 (63.1)  23 191 (44)  0.01  
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 LDH; U/L 120-220  25 193.5 (36.6)  23 191 (24.9)  0.79  
 ZTT; U 0-5  25 6.3 (3.8)  10 6.4 (1.9)  0.94  
 Total cholesterol; mg/dL 130-219  17 202.9 (41)  23 206.7 (23.6)  0.71  
 HDL cholesterol; mg/dL 40-100  27 65.4 (17)  23 63.6 (18.2)  0.73  
 LDL cholesterol; mg/dL 65-139  27 121.4 (37.2)  23 123.3 (26)  0.83  
 Triglyceride; mg/dL 30-149  27 111.1 (75.8)  23 108.1 (46.1)  0.87  
 Blood glucose; mg/dl 80-109  27 112.9 (36.3)  23 109.9 (49.1)  0.80  
 HbA1c_JDS; % 4.3-5.8  27 5.6 (1.1)  23 5.4 (0.8)  0.61  
 BUN; mg/dL 8-20  19 15.9 (5.4)  0 Unmeasured   
 Cr; mg/dL Male: 0.5-1.0; Female: 0.4-0.8  27 0.7 (0.2)  23 0.7 (0.2)  0.74  
 e-GFR Male: 80-100; Female: 64-80  10 84.6 (30.5)  13 75.9 (15)  0.38  
  UA; mg/dL Male: 3.5-7.0; Female: 2.5-6.0   27 5.7 (1.1)   23 5.6 (1.5)   0.94  
ALP, alkaline phosphatase; BUN, blood urea nitrogen; Cr, creatinine; e-GFR, estimated Glomerular Filtration Rate; GOT, glutamate oxaloacetate transaminase; 
GPT, glutamate pyruvate transaminase; Hb, hemoglobin; HbA1c_JDS, hemoglobin A1c (Japan Diabetes Society value); Ht, hematocrit; LDH, lactase 
dehydrogenase; RBC, red blood cell; SD, standard deviation; UA, urinary acid; WBC, white blood cell; ZTT, thymol turbidity test; γ-GTP; γ-glutmyl transferase 
a Reference values are mainly obtained from Standard Textbook of Internal Medicine 8th edition written in Japanese. 
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Table 5. Height and ALP value between the exposed and unexposed group, separated by 
sex. 
    Exposed   Unexposed   p value 
    N mean (SD)   N mean (SD)     
Male (n=24)         
 Height; cm 14 161.8 (7.1)  10 168.6 (7)  0.03  
 ALP; U/L 13 215.4 (70)  10 190.4 (45)  0.34  
Female  (n=26)        
 Height; cm 13 148.1 (9)  13 156.3 (5.9)  0.01  
 ALP; U/L 13 255.2 (46.9)  10 191.4 (45)  0.00  
ALP, alkaline phosphatase; SD, standard deviation 
 0 
